Why are some US RCC brands standing out more than others?
There are various options available to US oncologists to treat renal cell carcinoma (RCC). Clearly some of these options are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors?
NPS+ RCC (US) gives a unique insight into the overall brand health of 10 leading treatments for RCC currently being used in North America. 100 oncologists were surveyed on key issues including brand messaging, prescribing behaviour and satisfaction levels. The results provide valuable insight for brand marketers seeking new ways to stand out.
Interested in the European market? Click here to see the EU5 Edition.
- One brand leads the way, and the rest don’t even get close. Of the 10 brands included in the survey, one brand is just under 20 points ahead of second place, and 7/10 brands don’t even achieve a positive NPS. Which one leads the way, and where are the key fights for lower places?
- Loyalty is proving difficult to achieve. Loyalty scores of 4 or more are what brands are aiming for, but for RCC treatments, even the highest scores are not even close in this latest survey. Is clinical differentiation really that low?
- Despite low loyalty, satisfaction is high. Why are oncologists so happy with the numerous drugs on offer? And is there any more that could be done to improve satisfaction scores even more?
- Marketing messaging could be the key. Which brands are associated with key issues such as safety, efficacy, convenient administration and cost effectiveness? Could more be done to promote key benefits?
- In their own words. What do doctors say each brand means to them? For example, which brand is described as ‘one of the most effective agents for RCC’ and which brand is ‘no longer useful’?
Insight into 10 RCC Treatments
- Afinitor (everolimus; Novartis)
- Avastin (bevacizumab; Roche)
- Cabometyx (cabozantinib; Exelixis)
- Inlyta (axitinib; Pfizer)
- Lenvima (lenvatinib; Eisai/Novartis)
- Nexavar (sorafenib; Bayer/Amgen)
- Opdivo (nivolumab; Bristol-Myers Squibb)
- Sutent (sunitinib; Pfizer)
- Torisel (temsirolimus; Pfizer)
- Votrient (pazopanib; Novartis)
Explore Important Brand Loyalty Issues
NPS+ RCC (US) offers valuable insight into brand loyalty from the perspective of those currently prescribing treatments for RCC to patients. You’ll discover:
- Exactly how satisfied the US market is.
- How loyal doctors are to your brand.
- How many other brands your Promoters recommend.
- Which other brands your Promoters and Detractors recommend.
- How much market share your brand has among Promoters and Detractors.
- How much more of a brand Promoters prescribe than Detractors.
- Which messages Promoters, Passives and Detractors associate with your brand.
- Your brand DNA: what doctors really think of your brand—in their own words.
A Report Based on Expert Knowledge
We surveyed 100 US-based oncologists chosen from the largest community of validated physicians in the world. We conducted the survey between January 10-20, 2018.
What is Net Promoter® Score?
NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.
How does NPS work?
NPS measures overall brand satisfaction and loyalty by asking one simple question:
"How likely are you to recommend this brand to a colleague?"
Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)—are used to classify respondents into 3 categories:
Detractors are those who answer 0 – 6.
Passives are those who answer 7 – 8.
Promoters are those who answer 9 - 10.
How is NPS calculated?
The percentage of detractors - the percentage of promoters = NPS.
For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.
NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.
What is FirstView NPS+?
Each NPS+ report examines doctors’ relationships with the brands used to treat a major disease area—measuring brand loyalty and showing you how it affects your market share. NPS+ also examines “brand DNA”, revealing in doctors’ own words what brands mean to them.
Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.
Money Back Guarantee!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
- FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
- FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Learn more at www.firstwordgroup.com.